Bone marrow provides an environment that prevents suppression of therapeutic graft-vs.-tumor immunity by regulatory T cells

por Guichelaar, Teun, Mutis, Tuna
Publicado 2013

Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance

por Holthof, Lisa C., Mutis, Tuna
Publicado 2020

The Connection Between Minor H Antigens and Neoantigens and the Missing Link in Their Prediction

por Mutis, Tuna, Xagara, Anastasia, Spaapen, Robbert M.
Publicado 2020

Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells

por Abdi, Jahangir, Mutis, Tuna, Garssen, Johan, Redegeld, Frank
Publicado 2013

Toll-Like Receptor (TLR)-1/2 Triggering of Multiple Myeloma Cells Modulates Their Adhesion to Bone Marrow Stromal Cells and Enhances Bortezomib-Induced Apoptosis

por Abdi, Jahangir, Mutis, Tuna, Garssen, Johan, Redegeld, Frank A.
Publicado 2014

Interleukin-17 production and T helper 17 cells in peripheral blood mononuclear cells in response to ocular lysate in patients with birdshot chorioretinopathy

por Kuiper, Jonas J.W., Emmelot, Maarten E., Rothova, Aniki, Mutis, Tuna
Publicado 2013

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

por van der Horst, Hilma J., Nijhof, Inger S., Mutis, Tuna, Chamuleau, Martine E. D.
Publicado 2020

Targeted Therapy With Immunoconjugates for Multiple Myeloma

por Bruins, Wassilis S. C., Zweegman, Sonja, Mutis, Tuna, van de Donk, Niels W. C. J.
Publicado 2020

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment

por van der Schans, Jort J., van de Donk, Niels W. C. J., Mutis, Tuna
Publicado 2020

Immunotherapy in myeloma: how far have we come?

por Franssen, Laurens E., Mutis, Tuna, Lokhorst, Henk M., van de Donk, Niels W. C. J.
Publicado 2019

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy

por de Jonge, A. Vera, Mutis, Tuna, Roemer, Margaretha G. M., Scheijen, Blanca, Chamuleau, Martine E. D.
Publicado 2020

Minor H Antigen HA-1–specific Regulator and Effector CD8(+) T Cells, and HA-1 Microchimerism, in Allograft Tolerance

por Cai, Junchao, Lee, Junglim, Jankowska-Gan, Ewa, Derks, Richard, Pool, Jos, Mutis, Tuna, Goulmy, Els, Burlingham, William J.
Publicado 2004

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design

por Drent, Esther, Poels, Renée, Mulders, Manon J., van de Donk, Niels W. C. J., Themeli, Maria, Lokhorst, Henk M., Mutis, Tuna
Publicado 2018

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma

por Hosny, Mashhour, Verkleij, Christie P. M., van der Schans, Jort, Frerichs, Kristine A., Mutis, Tuna, Zweegman, Sonja, van de Donk, Niels W. C. J.
Publicado 2021

Toward targeting B cell cancers with CD4(+) CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis

por Spaapen, Robbert M., Lokhorst, Henk M., van den Oudenalder, Kelly, Otterud, Brith E., Dolstra, Harry, Leppert, Mark F., Minnema, Monique C., Bloem, Andries C., Mutis, Tuna
Publicado 2008

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

por Drent, Esther, Groen, Richard, Noort, Willy, van Bueren, Jeroen Lammerts, Parren, Paul, Kuball, Jürgen, Sebestyen, Zsolt, van de Donk, Niels, Martens, Anton, Lokhorst, Henk, Mutis, Tuna
Publicado 2015

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

por Verkleij, Christie P. M., Jhatakia, Amy, Broekmans, Marloes E. C., Frerichs, Kristine A., Zweegman, Sonja, Mutis, Tuna, Bezman, Natalie A., van de Donk, Niels W. C. J.
Publicado 2020

S187: IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL OUTCOME IN ELDERLY MULTIPLE MYELOMA PATIENTS

por Bruins, Wassilis, Duetz, Carolien, Groen, Kaz, Korst, Charlotte, de Jonge, Vera, Verkleij, Christie, Rentenaar, Rosa, Cosovic, Meliha, van de Donk, Niels W.C.J., Zweegman, Sonja, Mutis, Tuna
Publicado 2023

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

por Poels, Renée, Drent, Esther, Lameris, Roeland, Katsarou, Afroditi, Themeli, Maria, van der Vliet, Hans J., de Gruijl, Tanja D., van de Donk, Niels W. C. J., Mutis, Tuna
Publicado 2021

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

por van de Donk, Niels W. C. J., Janmaat, Maarten L., Mutis, Tuna, Lammerts van Bueren, Jeroen J., Ahmadi, Tahamtan, Sasser, A. Kate, Lokhorst, Henk M., Parren, Paul W. H. I.
Publicado 2016